The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Case Report

Amiodarone-induced Alveolar Hemorrhage

Authors: Said B. Iskandar, MD, Bernard Abi-Saleh, MD, Rob L. Keith, MD, Ryland P. Byrd, Jr, MD, Thomas M. Roy, MD

Abstract

Abstract:Amiodarone is increasingly prescribed for patients with ventricular and supraventricular tachyarrhythmias. Many adverse effects have been reported due to this drug and include injury to the liver, thyroid, cornea, skin, and neuromuscular system. Pulmonary toxicity is one of the more serious side effects of this anti-arrhythmic drug and is potentially fatal. Since the first case of amiodarone-induced pneumonitis was described in the early 1980s, amiodarone pneumonitis has been recognized as a distinctive and not uncommon form of drug-induced lung injury. On the other hand, amiodarone-induced pulmonary toxicity resulting in alveolar hemorrhage is rare. The authors report a patient with amiodarone-induced alveolar hemorrhage and review the literature.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Connolly SJ. Evidence based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025–2034.
 
2. Brinker A, Johnston M. Acute pulmonary injury in association with amiodarone, Chest2004;125:1591–1592.
 
3. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417–1424.
 
4. Magro SA, Lawrence EC, Wheeler SH, et al. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 1988;12:781–788.
 
5. Kudenchuk PJ, Pierson DJ, Greene HL, et al. Prospective evaluation of amiodarone pulmonary toxicity. Chest 1984;86:541–548.
 
6. Dean PJ, Groshart KD, Porterfield JG, et al. Amiodarone-associated pulmonary toxicity: a clinical and pathologic study of eleven cases. Am J Clin Pathol 1987;87:7–13.
 
7. Iskander S, Raible DG, Brozena SC, et al. Acute alveolar hemorrhage and orthodeoxia induced by intravenous amiodarone. Catheter Cardiovasc Interv 1999;47:61–63.
 
8. Goldstein I, Topilsky M, Segev D, et al. Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. Chest 1997;111:1446–1447.
 
9. Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest 1994;105:305–306.
 
10. Camus P, Martin II, WJ Rosenow EC III. Amiodarone pulmonary toxicity. Clin Chest Med2004;25:65–75.
 
11. Zitnik RJ. Drug-induced lung disease: anti-arrhythmic agents. J Respir Dis 1996;17:254–270.
 
12. Valle JM, Alvarez D, Antunez J, et al. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J 1995;8:470–471.
 
13. Arnon R, Raz I, Chajek-Shaul T, et al. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest 1998;93:425–427.
 
14. Naccarelli GV, Wolbrette DL, Patel HM, et al. Amiodarone: clinical trials. Curr Opin Cardiol2000;15:64–72.
 
15. Morady F, Sauve MJ, Malone P, et al. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1983;52:975–979.
 
16. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity: recognition and pathogenesis. Chest1988;93:1067–1075.
 
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
 
18. Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004;25:25–35.
 
19. Grebski E, Hess T, Hold G, et al. Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage. Chest 1992;102:1794–1799.
 
20. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002;121:19–23.
 
21. Fraire AE, Guntupalli KK, Greenberg SD, et al. Amiodarone pulmonary toxicity: a multi-disciplinary review of current status. South Med J 1993;86:67–77.
 
22. Gutierrez R, Del Pozo, J Carrion C, et al. Vasculitis associated with amiodarone treatment. Ann Pharmacother 1994;28:537.
 
23. Zaher C, Hamer A, Peter T, et al. Low dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. N Engl J Med 1983;308:779.
 
24. Singh BN. Amiodarone: the expanding anti-arrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608–618.